Tag: Filament Health Corp.

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER

The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF)...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsFilament Health Corp.

Alvopetro Announces June 2025 Sales Volumes

Oxford Business Group and Oman Investment Authority highlight sultanate’s economic transformation in new advisory report

MTY Food Group Inc Will Hold a Conference Call to Discuss Its Second Quarter Results

Tag: Filament Health Corp.

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us